Week of August 31st, 2020 | Vol. 9, Issue 35
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Aspen
Sell-side | Pharma Services | Multi-national contract manufacturing and packaging organization

Project Athena
Sell-side | Medical Device | Novel medical device for the treatment of pelvic organ prolapse

Project Vista
Out-partnering | Pharma | Seeking commercial partner for novel, liquid-format riluzole treatment of ALS

Project Seal
Buy-side | Pharma | Seeking Pain and CNS products as well as legacy/tail commercial pharma assets

Project Olympus
Sell-side | Pharma | Portfolio of generic injectable products
Pfizer has signed a new three-year deal with contract research organization Parexel, adding to its decade-long collab.

This is makes it four out of four for the New York-based Big Pharma, which has spent the few two months combing over and adding to its CRO pacts; first with Icon, then Syneos Health (the results of the INC Research and inVentiv Health merger in 2018), and the PPD.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
15 transactions totaling $3,278 million
Supplies, Equipment & Services
15 transactions totaling $980 million
Healthcare IT & Managed Care
4 transactions totaling $179 million
Healthcare Facilities & Distributors
6 transactions totaling $847 million
Pharma & Biotech
39 transactions totaling $873 million
Supplies, Equipment & Services
21 transactions totaling $499 million
Healthcare IT & Managed Care
18 transactions totaling $348 million
Healthcare Facilities & Distributors
2 transactions totaling $5 million
Pharma & Biotech
15 transactions totaling $482 million
Supplies, Equipment & Services
5 transactions totaling $127 million
Healthcare IT & Managed Care
2 transactions totaling $154 million
Healthcare Facilities & Distributors
4 transactions totaling $78 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
August 28, 2020 - Fierce Pharma
Takeda has agreed to sell its Japanese consumer health business to Blackstone Group after months of rumors. Bayer is adding a new manufacturing plant to its Beijing production site that could increase yearly output by 40%. Celltrion struck an agreement with Intract Pharma to develop the world's first oral biosimilar of Johson & Johnson's Remicade and more.

August 27, 2020 - Fierce Biotech
FDA Commissioner Stephen Hahn, M.D., was fresh off a controversy over the emergency use authorization for convalescent plasma to treat COVID-19 when he made waves again, this time promising on Twitter that the agency would review coronavirus vaccines before the November election. And Pfizer executives appear to be in sync with that timeline, as they race to complete a phase 3 trial of their vaccine candidate.

August 26, 2020 - Fierce Pharma
With the walls closing in around it on a yearslong generics price-fixing probe, Israeli drugmaker Teva faced two options: Reach a deal with prosecutors or gamble. Teva chose to roll the dice, and now it finds itself facing conspiracy charges—and a potentially bigger penalty on the horizon.

August 27, 2020 - Contract Pharma
Piramal Pharma Solutions (PPS) is providing Epirium with integrated services encompassing formulation development, supply of APIs and intermediates, chemistry development and manufacturing, and solid oral dosage form drug product. The work is being completed across three PPS sites in India, with the seamless alignment of information, technology, and project management that aims to speed timelines.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.